Abbott Laboratories: This Dividend Growth King Has Rarely Been So Cheap

Abbott Laboratories is rated Buy with a $126 12-month price target, supported by 7%-8% revenue growth and a 52-year dividend growth streak. The Exact Sciences acquisition temporarily trims 2026 EPS by $0.20/share, but adds a high-growth oncology diagnostics platform and supports longer-term secular growth. Shares trade at 17.7x forward earnings, a 10-year low valuation, suggesting a compelling entry point despite the near-term dilution.

Analysis

The market is treating this as a simple dilution story, but the more important effect is that ABT is effectively buying duration: it is exchanging near-term EPS for a higher-quality growth vector that can re-rate the multiple over the next 12-24 months if execution is clean. At 17-18x forward earnings, the stock is being priced like a slow defensive compounder even though the portfolio mix is shifting toward a category with materially higher secular growth and less dependence on hospital capex cycles. That creates asymmetry if management can keep core margins intact while integrating the asset without a prolonged distraction period.

The second-order winners are likely adjacent diagnostics and oncology workflow providers, because a larger incumbent can accelerate test adoption through existing physician relationships, reimbursement infrastructure, and commercial coverage. The losers are smaller single-product diagnostics names that now face a better-capitalized competitor with a broader sales force and a lower cost of customer acquisition. The real risk is not the headline EPS hit; it is whether the acquired growth engine requires more integration spend or pricing concessions than the market is currently modeling, which would push the payback period out by 2-3 quarters.

The consensus may be underestimating how much of the current selloff is technical rather than fundamental. Dividend-oriented holders are likely providing a floor, but a clean re-entry usually comes only once management shows the acquired asset can offset dilution faster than expected and that the core business still sustains mid/high-single-digit growth. If that happens, the stock can de-rate back toward a premium defensive multiple; if not, the market will keep ABT trapped in the 16-18x range despite the growth narrative.

Catalyst timing matters: near term, expect the stock to trade on integration commentary and guidance credibility rather than on long-dated oncology upside. Over the next 3-6 months, any hint that the EPS dilution is front-loaded and temporary should tighten the valuation gap; over 12 months, reimbursement or adoption friction would be the main reason the thesis fails. The best risk/reward is to own the base business while limiting exposure to integration disappointment.

Key Decisions for Investors

• Long ABT on a 6-12 month horizon: use weakness from integration headlines to build a position; target 15-20% upside if the multiple re-rates toward a mid/high-teens premium defensive peer valuation, with downside cushioned by dividend support.
• Pair trade: long ABT / short a basket of smaller diagnostics names over the next 3-9 months; thesis is that a scaled platform with reimbursement and salesforce advantages can absorb growth assets more efficiently, compressing the relative valuation of subscale competitors.
• If options liquidity is adequate, buy ABT 6-9 month calls or call spreads instead of stock into the next earnings cycle; the setup is for a delayed positive surprise once management proves the EPS drag is temporary, making defined-risk upside attractive.
• Avoid chasing EXAS on the deal optics alone; if there is a post-close overhang, wait for a clear read on integration and reimbursement before considering any long, since the market may be overestimating standalone upside after the transaction.
• Add/maintain ABT only on confirmation that core organic growth stays 7%+ and the acquired asset does not require repeated guide-downs; if guidance slips twice, cut exposure because the multiple can stay stuck despite the dividend.